Safety and Efficacy of OBX-115 in Advanced Solid Tumors
NCT06060613
This study is recruiting at 8 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Tumor Skin
- Metastatic Melanoma
- Melanoma
- Lung Cancer
- Metastatic Lung Cancer
- Non Small Cell Lung Cancer
- Metastatic Non Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Obsidian Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- October 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- The Angeles Clinic and Research Institute (Melanoma) · Los Angeles, CA
- USC Norris Comprehensive Cancer Center (Melanoma/NSCLC) · Los Angeles, CA
- Stanford Cancer Institute (Melanoma/NSCLC) · Stanford, CA
Florida · 1
- Orlando Health Cancer Institute (Melanoma/NSCLC) · Orlando, FL
Kentucky · 1
- James Graham Brown Cancer Center (Melanoma/NSCLC) · Louisville, KY
New York · 1
- Memorial Sloan Kettering (Melanoma/NSCLC) · New York, NY
Pennsylvania · 1
- Allegheny Research Institute (Melanoma/NSCLC) · Pittsburgh, PA
Texas · 1
- M.D. Anderson Cancer Center (Melanoma/NSCLC) · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.